腹腔热灌注化疗治疗胃癌的研究现状

胃癌患者预后差的主要原因是腹膜转移,既往的姑息性手术及全身化疗治疗模式对其疗效差.近年来腹腔热灌注化疗(hyperthermic intraperitoneal chemotherapy,HIPEC)以及围绕其开展的综合治疗模式的临床研究不断进行,证实HIPEC不仅可以预防胃癌根治术后腹膜转移,还可改善部分腹膜转移患者...

Current status of hyperthermic intraperitoneal chemotherapy in gastric cancer patients

The main reason of poor prognosis in gastric cancer patients is peritoneal metastasis. The effectiveness of traditional treatment modality, including systematic chemotherapy and/or palliative surgery, is disappointing due to the poor survival rate and quality of life. In recently years, clinical studies of hyperthermic intraperitoneal chemotherapy (HIPEC) and comprehensive treatment model centering HIPEC have been carried out continuously. It has been confirmed that HIPEC can not only prevent peritoneal metastasis after radical resection of gastric cancer, but also improve both the survival and the quality of life in selected patients with peritoneal metastasis. This article reviews the current status of HIPEC in gastric cancer from the aspects of mechanism, drug selection, treatment model and efficacy evaluation and prognosis related biomarkers.